<DOC>
	<DOCNO>NCT00525239</DOCNO>
	<brief_summary>Hypothesis 1 : Ritonavir-based regimen increase triglyceride VLDL increase VLDL production decrease VLDL clearance . Specific Aim 1A : To quantify effect ritonavir VLDL production clearance use stable isotope turnover clearance method . Specific Aim 1B : To determine composition triglyceride rich particle . Protocol 1 : The effect ritonavir-based regimen VLDL production , VLDL clearance triglyceride-rich lipoprotein composition healthy normal volunteer . HIV-seronegative volunteer study end four week take ritonavir , lopinavir/ritonavir atazanavir/ritonavir . Hypothesis 2 : NNRTI drug increase HDL increase apo AI production , rather decrease apo AI clearance , prolong time circulation . Specific Aim 2A : To determine composition HDL NNRTI ass function . Specific Aim 2B : To quantify effect NNRTI apo AI production clearance use stable isotope . Specific Aim 2C : To determine NNRTI induced increase HDL accompany improvement flow mediate vasodilation circulate marker endothelial function Protocol 2A : The effect efavirenz HDL composition , HDL function , apo AI production , apo AI clearance , flow mediate vasodilation circulate marker endothelial dysfunction healthy normal volunteer . HIV-seronegative volunteer study end six week take efavirenz . Protocol 2B : The effect start efavirenz-based regimen HDL composition , HDL function , apo AI production , apo AI clearance , flow mediate vasodilation circulate marker endothelial dysfunction patient HIV infection . HIV-infected patient whose care provider prescribe efavirenz-based regimen study six week start efavirenz . Hypothesis 3 : Ritonavir-based PI regimens impair insulin secretion . Specific Aim 3 : To determine ritonavir-based PI regimens alter insulin secretion . Protocol 3 : The effect ritonavir-based regimen insulin secretion healthy normal volunteer . HIV-seronegative volunteer study end four week take ritonavir , lopinavir/ritonavir atazanavir/ritonavir .</brief_summary>
	<brief_title>HIV Antiretroviral Drugs Metabolism</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Protocols 1 , 2A 3 HIV negative , healthy normal volunteer , age &gt; 18 year old . Protocol 2B HIVinfected subject , age &gt; 18 year old document HIV1 infection â‰¥ 6 month , start efavirenz health care provider . Protocols 1 , 2A 3 Coronary artery disease , peripheral vascular disease , impair fast glucose ( glucose &gt; 100 mg/dl ) , obese ( BMI &gt; 30 ) , dyslipidemia ( triglyceride &gt; 190 mg/dl , LDLC &gt; 190 ) , anemia ( Hct &lt; 39 ) , hypertension ( BP &gt; 140/90 mmHg medication ) , blood pressure &lt; 100 mmHg , renal disease ( creatinine &gt; 1.6 ) , LFT &gt; ULN , use within 30 day systemic glucocorticoid , anabolic steroid , growth hormone , niacin , antipsychotic , lipid lower medication . Women test pregnancy immediately prior inpatient study exclude pregnant . For Specific Aim 2 , additional exclusion criterion include history depression require treatment , psychosis , hallucination delusion ; use cGMP specific phosphodiesterase 5 inhibitor ( e.g. , sildenafil ) within 7 day study ; history adverse reaction nitrate . Protocols 1 , 2A 3 Currently NNRTI , coronary artery disease , peripheral vascular disease , recent opportunistic infection ( within two month ) , impaired fasting glucose ( glucose &gt; 100 mg/dl ) diabetes , anemia ( Hct &lt; 39 ) , hypertension ( BP &gt; 140/90 mmHg medication ) , blood pressure &lt; 100 mmHg , renal disease ( Creatinine &gt; 1.6 ) , LFT &gt; 2x ULN , use cGMP specific phosphodiesterase 5 inhibitor ( e.g. , sildenafil ) within 7 day study , history adverse reaction nitrate , use within 30 day anabolic steroid , systemic glucocorticoid , growth hormone , niacin , antipsychotic , lipid lower medication . Women test pregnancy immediately prior inpatient study exclude pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Lipids</keyword>
	<keyword>lipoprotein</keyword>
	<keyword>VLDL</keyword>
	<keyword>triglyceride</keyword>
	<keyword>apo B100</keyword>
	<keyword>HDL</keyword>
	<keyword>apo A1</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>insulin secretion</keyword>
	<keyword>hyperglycemic clamp</keyword>
	<keyword>HIV-seronegative Volunteers</keyword>
	<keyword>HIV-infected subject start efavirenz-based regimen</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>